Asset Details
Do you wish to reserve the book?
Pan-cancer circulating tumor DNA detection in over 10,000 Chinese patients
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Pan-cancer circulating tumor DNA detection in over 10,000 Chinese patients
Do you wish to request the book?
Pan-cancer circulating tumor DNA detection in over 10,000 Chinese patients
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Pan-cancer circulating tumor DNA detection in over 10,000 Chinese patients
2021
Overview
Circulating tumor DNA (ctDNA) provides a noninvasive approach to elucidate a patient’s genomic landscape and actionable information. Here, we design a ctDNA-based study of over 10,000 pan-cancer Chinese patients. Using parallel sequencing between plasma and white blood cells, 14% of plasma cell-free DNA samples contain clonal hematopoiesis (CH) variants, for which detectability increases with age. After eliminating CH variants, ctDNA is detected in 73.5% of plasma samples, with small cell lung cancer (91.1%) and prostate cancer (87.9%) showing the highest detectability. The landscape of putative driver genes revealed by ctDNA profiling is similar to that in a tissue-based database (R
2
= 0.87,
p
< 0.001) but also shows some discrepancies, such as higher
EGFR
(44.8% versus 25.2%) and lower
KRAS
(6.8% versus 27.2%) frequencies in non-small cell lung cancer, and a higher
TP53
frequency in hepatocellular carcinoma (53.1% versus 28.6%). Up to 41.2% of plasma samples harbor drug-sensitive alterations. These findings may be helpful for identifying therapeutic targets and combined treatment strategies.
The detection of aberrations in circulating tumour DNA represents a non-invasive method to survey the oncogenes and tumour suppressors that are modified within a patient’s cancer. Here, the authors analysed more than 10,000 patients using a targeted sequencing panel and report on the frequencies of the mutations that they found.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
/ 45/23
/ Asian Continental Ancestry Group - genetics
/ Circulating Tumor DNA - analysis
/ Circulating Tumor DNA - blood
/ Circulating Tumor DNA - genetics
/ DNA
/ Epidermal growth factor receptors
/ Humanities and Social Sciences
/ Humans
/ Mutation
/ Non-small cell lung carcinoma
/ Patients
/ Plasma
/ Science
/ Tumors
